| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5813365 | Neuropharmacology | 2016 | 34 Pages |
Abstract
The present study suggests the preclinical efficacy of a strategy based on the blockade of 5-HT5A receptors against schizophrenia-like cognitive deficits and negative symptoms. The utility of this receptor as a target for improvement of cognitive and social dysfunctions warrants further studies.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Agnieszka Nikiforuk, MaÅgorzata HoÅuj, Tomasz Kos, Piotr Popik,